Intranasal H107e
Phase 1Biologic
Intranasal H107e is one of 33 biologic programs targeting Tuberculosis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
297 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Rifadin
SanofiPhase 3
Avelox
BayerPhase 3
Lamprene
NovartisPhase 3
Sirturo
WWim Janssens
Phase 3
Onbrez
NovartisPhase 3
Bayer Aspirin
BayerPhase 3
TB Alliance
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
BCG Vaccine
GGynecologic Oncology Group
Phase 3
Selenium
SSWOG Cancer Research Network
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intranasal H107e. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SStatens Serum Institut